Physician profile
Mark D Lehman
NPI 1932195815
$16,806.76
in general payments reported to CMS, 2019-2025
38 companies · $3,109 in 2025
The $3,109 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,425 · 2020: $1,171 · 2021: $1,426 · 2022: $2,764 · 2023: $2,846 · 2024: $3,065 · 2025: $3,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,013 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,013.43 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,689.75 | 2019-2025 | |
| Lilly USA, LLC | $1,348.47 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,276.67 | 2019-2025 | Tremfya, Spotlight |
| Sun Pharmaceutical Industries INC. | $1,121.37 | 2019-2025 | Odomzo, Blu-U, Winlevi |
| Regeneron Healthcare Solutions, INC. | $936.02 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $872.62 | 2019-2025 | |
| Leo Pharma INC. | $822.44 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $806.52 | 2019-2025 | |
| Amgen INC. | $770.63 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $702.87 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $526.21 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $455.79 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $409.87 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Incyte Corporation | $404.49 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $364.11 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $333.14 | 2019-2025 | |
| Ucb, INC. | $322.19 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $278.78 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $257.34 | 2020-2021 | |
| Dermavant Sciences, INC. | $179.44 | 2022-2024 | Vtama |
| Celgene Corporation | $136.02 | 2019 | |
| Comsort, INC | $100.00 | 2019 | |
| Prugen, INC. Pharmaceuticals | $92.02 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $88.55 | 2019 | |
| Kyowa Kirin, INC. | $84.42 | 2019-2023 | Poteligeo |
| Sandoz INC. | $73.22 | 2019-2025 | Hyrimoz |
| Organon LLC | $65.78 | 2025 | Vtama |
| Allergan, INC. | $56.38 | 2022 | |
| Almirall LLC | $42.30 | 2021-2023 | Klisyri |
| Biofrontera INC. | $33.27 | 2019-2020 | |
| Dermira, INC. | $30.00 | 2019 | |
| Krystal Biotech INC | $25.97 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $21.72 | 2024 | Ycanth |
| Encore Dermatology INC. | $20.55 | 2020 | |
| Fresenius Kabi USA, LLC | $17.89 | 2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.59 | 2024 | Spevigo |
| Promius Pharma LLC | $12.40 | 2019 | |
| Merck Sharp & Dohme LLC | $9.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.